Ask about this productRelated genes to: UCHL1 Blocking Peptide
- Gene:
- UCHL1 NIH gene
- Name:
- ubiquitin C-terminal hydrolase L1
- Previous symbol:
- PARK5
- Synonyms:
- PGP9.5, Uch-L1
- Chromosome:
- 4p13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-15
- Date modifiied:
- 2015-11-13
Related products to: UCHL1 Blocking Peptide
Related articles to: UCHL1 Blocking Peptide
- Colorectal cancer (CRC) is a prevalent malignant tumor with increasing incidence and mortality rates worldwide. Exosomes are secretory vesicles generated by the endosomal system within cells. Previous studies have reported that exosome-related genes (ERGs) are associated with the progression of malignancies. This study investigates the role of ERGs in CRC, evaluates their impact on CRC prognosis, and explores inter-individual differences among CRC patients in different risk groups. - Source: PubMed
Publication date: 2026/07/04
Wang KaisongChen TingyuChen YiqiangZhao JiajingFu RuizhiXu XiaolingSu GenghongChen Shubiao - Timely and accurate diagnosis of mild traumatic brain injury (mTBI) remains challenging in acute care. In the Asia-Pacific (APAC) region, marked heterogeneity in healthcare infrastructure, computed tomography (CT) utilization, and diagnostic pathways underscores the need for practical, standardized approaches to assessment. Blood-based biomarkers, particularly glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), have shown promising diagnostic performance and have been incorporated into clinical pathways in other regions. However, their role in APAC emergency care workflows has not been systematically addressed. This study aimed to develop expert consensus on the definition, diagnosis, and clinical integration of these biomarkers into mTBI assessment across APAC. - Source: PubMed
Publication date: 2026/07/03
Kuan Win SenVeerasarn KullapatJoseph MathewMusikatavorn KhrongwongChung KongPrasert YodrukZairinal Ramdinal AviesenaCordero Jeremy AShukla DhavalMitra Biswadev - Small cell carcinoma of the uterine cervix (UCSCC) is a rare and aggressive HPV-linked neuroendocrine malignancy with limited therapeutic options and poor prognosis. Through integrative analysis of whole-exome sequencing (WES), single-cell RNA-seq (scRNA-seq), PinpoRNA-HPV, bulk RNA-sequencing, and immunohistochemistry (IHC), we delineated its molecular architecture. Genomic profiling unveiled the dysregulation of 10 core oncogenic pathways and an exceptionally high tumor mutational burden (TMB), along with frequent alterations in DNA repair genes. ScRNA-seq analysis identified nine distinct malignant subclusters characterized by lineage plasticity (ASCL1/NEUROD1/UCHL1) alongside active HPV18 transcription. The tumor microenvironment exhibited a paradoxical immune landscape: dense infiltration of CD8+ T cells and CD163+ tumor-associated macrophages (TAMs) in the complete absence of tumoral PD1/PD-L1 expression. Cell-cell communication analysis revealed that malignant subclusters specifically overexpress CD47, engaging SIRB1 on TAMs and SIRPG on T cells. IHC validation confirmed a CD8+/CD163+/PD-L1-phenotype and demonstrated that transcriptional CD47 enrichment in malignant clones implicated the CD47-SIRB1 axis as the primary immune checkpoint. These findings indicated UCSCC as an HPV-driven, heterogeneous tumor that might employ CD47 as an alternative immune evasion pathway in the absence of PD-L1, providing a strong rationale for exploring CD47 blockade as a novel potentially therapeutic strategy. - Source: PubMed
Publication date: 2026/07/03
Zhang QingxinFu JianjiangZhong LiuyingYang ZiyangWeng CanZhong XinFang ShunLiu ShaoyanCai TonghuiSheng XiujieGao HongyiPeng Juan - To determine whether blood-based biomarkers in the first days of life could specifically predict cerebral palsy (CP) and/or cognitive/language delay in infants with moderate-severe HIE. - Source: PubMed
Publication date: 2026/07/01
Clifford Mrcpi DanielleVaughan Conor LCostelloe Seán JWalsh Brian HNumis AdamJuul Sandra EMurray Deirdre M - Alpha-lipoic acid (ALA) is a natural compound present in plants, animals, and humans. It provides neuroprotection through its antioxidant action, reducing oxidative stress and inflammation via pathways such as the Nrf-2 signalling pathway. It has shown protective effect against neuronal damage in Alzheimer's disease and Parkinson's disease. The traumatic brain injury (TBI) is a major cause of cognitive and motor impairments. TBI primarily initiates a series of secondary injury pathways, with glutamate excitotoxicity being a critical factor in neuronal degeneration. In this study, we investigated the protective effects of ALA on TBI induced by controlled cortical impact (CCI) in the cerebral cortex (CC) and hippocampus (HC) regions of the Wistar rats. TBI parameters were analysed using behavioural assays, including the Barnes maze test (BMT), beam balance test, grip strength, and Y-maze test (YMT). In addition, we measured brain water content, and analyzed histological alterations by light microscopy, microglial changes by the immunofluorescence technique, and ultrastructural changes by the transmission electron microscopy (TEM). Expression of markers of glutaminergic and calcium (Ca⁺) pathways was analysed by qRT-PCR and western blotting. ALA was administered following TBI induction in rats. It was shown that ALA downregulated S100B and the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) mRNA expression. However, TBI-dependent alterations in excitatory amino acid transporter (EAAT) expression were downregulated in the CC region of adult rats with TBI. Protein expression of S100B, stromal interaction molecule (STIM), ubiquitin C-terminal hydrolase L1 (UCHL1), nuclear factor kappa (NF-ƙB), and glial fibrillary acidic protein (GFAP) was increased in the TBI group, as analysed by immunoblotting. Furthermore, expression of Iba1, a marker of microglial activation, was increased in TBI and mitigated by ALA. Overall, this study helps us understand the role of ALA as a mitigating compound in the TBI-induced rat model. - Source: PubMed
Publication date: 2026/07/01
Mazahir IqraWali BushraRehman Ahmed ShaneyDeep GauravMangla AnuradhaJindal GarimaKhan HumaParvez SuhelRaisuddin Sheikh